Graduation and Qualifications:

*   M.B.,B.Ch ., Faculty of Medicine, Cairo University, November 1987.

*   Master’s degree in cardiovascular diseases (M.Sc.), Cairo University, May 1992.

*   Doctorate degree in cardiovascular diseases (MD), Cairo University

,1997.

Previous and present positions and experience:

*     House officer, Cairo University Hospitals from 1/3 /1988 to 28/2 /1989

*     Resident, Cardiology department, Faculty of Medicine, Cairo University Hospitals from 1/9/1989 to 1/9/992

*     Clinical demonstrator in the department of cardiology, Faculty of Medicine, Cairo University from 10/9/1992 to 1/2/1993.

*     Assistant lecturer in the department of cardiology, Faculty of Medicine , Cairo University from 1/2/1993 to 23/10/1997.

*     Lecturer in the department of cardiology, Faculty of Medicine, Cairo University from 24/10/1997 till 24/10/2

*  Associate Professor of Cardiology, Faculty of Medicine, Cairo University from 24/10/2002 till 24/10/2007

*  Professor of Cardiology, Faculty of Medicine, Cairo University from 30/10/2007

till now

*  Chairman of the Cardiology Department, Kasr Al Ainy Faculty of Medicine , Cairo University from 15/9/2022 till now.

*  Professor of Cardiology, Armed College of Medicine since 2020 -2024

*   Postdoctoral Clinical Fellowship at the Heart Failure & Cardiac Transplantation center, The Brigham & Women’s Hospital, Harvard Medical School,1999.

*     Fellow of SCAI (The Society for Cardiovascular Angiography and

Interventions),USA,2011

*   Fellow of the American College of Cardiology (FACC), 2017

*   Diploma of Fellowship, Royal College of Physicians and Surgeons (FRCP) of Glasgow, February 2019

*   Fellow of the European Society of Cardiology (FESC), 2019

*   Fellow of the European Heart Failure Association (FHFA),2019

*Board Member of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020- 2022)

*Co-Chair of the Acute Heart Failure Scientific Committee of HFA, ESC

(2020- 2022)

*Co-Chair of the Valvular Heart Disease Scientific Committee of HFA, ESC (2020- 2022)

*Member of the Committee for Practice Guidelines, ESC (2020-2022)

*Chairman of the Educational Committee of the HFA, ESC (2022-2024)

*  Board member of the Accreditation Committee of the European Society of Cardiology (2022-2024)

*  Co-Chair of the Pharmacology Committee of the HFA, ESC (2024-2026)

*  Chairman of the Egyptian National Guidelines Committee of Cardiovascular Diseases, Egyptian Health Council.

Workshops:

•    Workshop in cardiovascular diseases update at Cleveland Clinic

. Ohio, USA. 2009

•    Workshop in complex coronary and peripheral intervention at Georg Pompidou hospital. Paris, France .2012

•    Workshop in TAVI at Georg Pompidou hospital. Paris, France

.2013

•    Workshop in complex coronary interventions at Georg Pompidou hospital. Paris, France .2014

•    The “CV summit: Hurghada, Egypt,18& 19 March 2016 Africa and Middle East (AFME), recent updates and approaches in preventive cardiology: from awareness to diagnosis and management of cardiovascular risk factors.

•    Workshop in thrombosis management in practice (TMIP) as a Regional Committee member of the TMIP program, London, November 2014

•    Workshop in complex coronary and peripheral intervention at Georg Pompidou hospital. Paris, France .2015

•    Workshop in complex coronary and peripheral intervention at San Rafael hospital. Rome, Italy .2015

•    Heart Failure Preceptorship at Charité Berlin, Germany November 24th and 25th, 2016

•    Workshop in complex coronary intervention and TAVI at Institute Cardiovascular Paris Sud hospital. Paris, France .2019

Memberships:

•    The American College of Cardiology (ACC)

•    The Society for Cardiovascular Angiography and Interventions( SCAI ) , USA

•    American Society of Echocardiography

•    European Society of Cardiology

•    European Association of Heart Failure

•    European Association of Cardiovascular Intervention (EAPCI)

•    Egyptian Society of Cardiology

•    Egyptian Hypertension Society (EHS)

•    National committee member of the transplantation program in Egypt

Current Positions:

-         Past President of the Egyptian Society of Cardiology (2018 - 2020).

-         President of the working group of heart failure, the Egyptian Society of Cardiology, 2017 till now.

-         General Secretary of the Egyptian society of cardiology (March 2016 –February 2018).

-         Secretary of the scientific committee upgrade for cardiology, Egyptian Universities Promotion Committees (February 2013 till September 2019).

-         National coordinator for the European Valvular Heart Disease (VHD II) Survey/Registry.

-         Nominated as a reviewer for the European guidelines of Valvular heart diseases, 2017.

-         Editorial board for the European Journal of Medicine, Interventional Cardiology, February 2017.

-         Editorial Board Reviewer for the ESC Heart Failure Journal, since June 2017.

-         Reviewer for the European Heart Journal

-         Senior Reviewer for the European Heart Journal, Case Reports since 2018.

-         International Advisory Board in the Journal of American College of Cardiology (JACC), Heart Failure Journal since March 2022

-         Regional consulting Editor for the European Journal of Heart Failure since

April 2024

-         Associate Editor for the Heart Failure Reviews Journal since October 2024

-         Editorial Board Reviewer for the Egyptian Heart Journal

-         Reviewer for the Chinese Medica Journal

-    Reviewer for the 2022 European Society of Cardiology (ESC) practice guidelines:

Heart failure

Valvular heart disease

Prevention of cardiovascular disease Pacing guidelines

- Reviewer for the 2023 European Society of Cardiology (ESC) practice guidelines:

Acute coronary syndrome Cardiomyopathies Endocarditis

Diabetes and cardiovascular disease

-Chairman of the Egyptian Guidelines Committee 2023

Awards and Prizes:

-         Cairo University Incentive award of Medicine, 2003

-         Certificate of Appreciating and Medal of excellence from Egyptian Medical Syndicate in Cairo 2003 for excellence in service to the

medical community

-         Certificate from Harvard medical school for excellent performance and successful contribution to the program of heart failure at Brigham and Women’s Hospital, 1999.

-         Certificate of Support to the World Heart Day 2018 &2019 from the World Heart Federation

-         Certificate of Recognition from the European Heart Failure Association (HFA) for a successful Heart Failure Awareness Day,2019

-         Cairo University Distinguished Award of Excellence 2024

Master & MD Thesis:

•    Master Thesis: Long-term follow-up after Balloon pulmonary valvotomy, Cairo University,1992

•    Doctorate Thesis: Dual-chamber pacing in hypertrophic cardiomyopathy, Cairo University,1996

Publications & Presentations (International)

1. Dual-chamber pacing in hypertrophic cardiomyopathy (Abs).

8th annual Mediterranean association of cardiology and cardiac surgery congress, Limassol – Cyprus,1995.

2.    Long-term clinical and echocardiographic follow-up after dual-chamber pacing in patients with hypertrophic obstructive cardiomyopathy (abst).Eleventh Annual Scientific meeting of the American Society of Echocardiography, Chicago, Illinois,2000.

3.    Long-term follow-up after permanent dual-chamber pacing in patients with hypertrophic obstructive cardiomyopathy (abst) .

XXII Congress of the European Society of Cardiology, Amsterdam, The Netherlands 2000.

4.    Pulmonary function tests, High-Resolution Computerized Tomography (HRCT) & alpha 1-antitrypsin measurement and early detection of pulmonary involvement in patients with systemic sclerosis.

The Rheumatology International, 2000.

5.    Circulating soluble adhesion molecules in patients with systemic sclerosis: correlation between circulating soluble vascular cell adhesion molecule –1 (sVCAM- 1) and impaired left ventricular diastolic function. Rheumatology International (2000) 20: 21-24

6-   Pulmonary hypertension in patients with chronic renal failure: The role of parathormone and pulmonary calcification (abst) .

The American College of Chest Physician, Philadelphia , Pennsylvania

,2001 . CHEST 2001, Scientific Highlights, 295S.

7-   Experience in a specialized heart failure unit in a tertiary care hospital in Egypt: demographic characteristics and in-hospital outcome of patients with severe heart failure (abst ).

Heart failure 2003, the annual congress of European Society of Cardiology, Strasbourg, France.

8-   Pulmonary hypertension in patients with chronic renal failure: The role of parathormone and pulmonary calcification.

CHEST, December 2003 Dec;124(6):2093-7

9-   Relations between von Willebrand factor, markers of oxidative stress, and microalbuminuria in patients with type 2 diabetes mellitus.

Med Sci Monit (International Clinical Research Journal ) , 2004 ., 10 (3) : CR85-89

10-   Signal Average ECG can predict left ventricular systolic dysfunction in patients with rheumatic mitral and or aortic regurgitation and dilated left ventricle (abst).

Heart failure 2004, the annual congress of European Society of Cardiology, Wroclaw, Poland.

11- Cardiac involvement in patients with systemic lupus erythematosus: Correlation with levels of Anti-Ro/SS-A and Anti-La/SS-B antibodies.

Modern Rheumatology, July, 2004

12-   Plasma level of brain natriuretic peptide has a diagnostic role in diastolic

heart failure (abst) .

-  EuroEcho, Athens, December 2004

-  XVI.Annual Mediterranean association of cardiology and cardiac surgery congress, Bodrum , Turkey, 2004

13-   Diastolic function abnormalities in rheumatoid arthritis: relation with disease duration and severity (abst) .

EuroEcho, Athens, December 2004

14-   Low ejection fraction is a predictor of creatine kinase –MB elevation and adverse cardiac events after coronary intervention (abst). XVI.Annual Mediterranean association of cardiology and cardiac surgery congress, Bodrum, Turkey, 2004

15-   Importance of creatine kinase – MB elevation after coronary intervention (abst) .

XVI. Annual Mediterranean association of cardiology and cardiac surgery congress, Bodrum, Turkey, 2004

16-   Oversize Inoue balloon is safe during balloon mitral valvotomy (abst

) . XVI. Annual Mediterranean association of cardiology and cardiac surgery congress, Bodrum , Turkey, 2004

17-   Mild or moderate creatine kinase – MB elevation after coronary angioplasty is not associated with adverse short-term clinical outcome (abst) International Academy of Cardiology,The 12th World congress on heart disease. Vancouver, BC, Canada, July,2005

18-   Coronary angioplasty after non-ST-elevation myocardial infarction carries a worse short-term outcome when compared to that of ST-elevation myocardial infarction or unstable angina (abst) .

International Academy of Cardiology, The 12th World congress on heart disease. Vancouver, BC, Canada, July 2005

19-   Right Ventricular Diastolic Function Abnormalities In Patients With Systemic Sclerosis

Euro Echo, Italy, December 2005

20-   E- selectin gene polymorphism: A risk factor for coronary artery diseases. Acute Cardiac Care, ESC, 2008

21-   Short-term efficacy of percutaneous transluminal alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

CRT, Washington, 2010

22-   Asymmetric dimethyl l-arginine, an endogenous inhibitor of nitric oxide synthase in congestive heart failure; relation to cardiac function.

Heart failure 2010, Berlin, the annual congress of European Society of Cardiology

23-   Adiponectin could be a new biomarker in acute coronary syndrome The European Society of Cardiology, Stockholm, 2010

24- Nightmare in the Cath Lab.

PCR, Paris, 2011

25- Management of acute coronary syndromes in developing countries: Acute Coronary Events—a multinational Survey of current management Strategies. The

ACCESS study. Am Heart J 2011; 162:852-859

26-   Endothelial progenitor cells mediate angiogenesis and coronary collateral formation in patients with chronic total coronary artery occlusion. Substudy in an experimental model (canines) with acute myocardial infarction.

CRT , Washington, 2012 (oral presentation )

27- Atrial preexcitation and a fixed S-A interval in relation to the fusion zone are superior to PPI-TCL in identifying SVT mechanism

Annual Congress of European cardiac arrhythmia Society (ECAS), 2012, Munich.

28-       Endothelial progenitor cells mediate angiogenesis and coronary collateral formation in patients with chronic total coronary artery occlusion, Euro PCR,2012. (oral presentation)

29-    Matrix metalloproteinase level can predict left ventricular remodeling and systolic dysfunction after myocardial infarction.

Heart failure 2012, Belgrade, the annual congress of European Society of Cardiology.

30-   Matrix metalloproteinase level can predict left ventricular remodeling and systolic dysfunction after myocardial infarction.

The European Society of Cardiology, Munich, 2012

31-   PCI for unprotected left main and the value of ST elevation in lead aVr in STEMI

Euro PCR ,2013 .(oral presentation)

32-   The role of interventionalist in treatment of cardiorenal syndrome in patients with heart failure. Euro PCR ,2013 .(oral presentation)

33-   PCI a few hours after non-indicated stress test. Euro PCR,2013

.(Interactive case corner presentation )

34-   Role of serum procalcitonin and high sensitivity C-reactive protein in distinguishing cardiac from pulmonary causes in patients with acute shortness of breath.

Heart failure 2013, Lisbon, the annual congress of the European Society of Cardiology.

35-   Should stable coronary artery disease patients without angina receive anti- ischemic therapy?

Medicographia 118 , 2014.vol 36.No 1 .

36- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes.

NEJM, 2013; 369:1327-35 (appendix)

37- Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry The European Journal of Heart Failure, 15(10),1173-84, 2013 (appendix)

38-   Low ankle-brachial index is not a predictor of adverse outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

CRT, Washington, February 2014

39-   How would you treat left main large thrombus burden during PCI of left

anterior Descending: aspirate, medicate, both or something else?

Euro PCR Paris, 2014. (Oral presentation)

40- Circulating EPCs predicts the occurrence of major adverse cardiac events and early adverse remodeling in patients with STEMI

Euro PCR 2014, Paris, (Poster )

41- Ischemia modified albumin is a new biomarker for early detection of myocardial injury in acute coronary syndromes

European Heart Failure, Athens, May 2014 (Poster)

42- Statin treatment increases the circulating endothelial progenitor cells and improves endothelial function in patients with coronary artery diseases The European Society of Cardiology, Barcelona, 2014 (Poster )

43-   Circulating EPCs predicts the occurrence of major adverse cardiac events and early adverse remodeling in patients with STEMI

The European Society of Cardiology, Barcelona, 2014 (Poster )

44-   Ischemia modified albumin is a new biomarker for early detection of myocardial injury in acute coronary syndromes

The European Society of Cardiology, Barcelona, 2014

Rapid Fire Abstract Session – Fast Paced and Interactive Abstract Presentation (oral presentation )

45- Left main thrombus management (oral presentation )

C3 conference (10th annular interventional meeting ), Orlando, USA

, June 2014

46-   Scar Characteristics for Prediction of Ventricular arrhythmia in Ischemic Cardiomyopathy. PACE journal, 2015;38:311–318

47-   Discrepancy between MRI and echocardiography in assessing functional left ventricular parameters and scar characteristics in patients with chronic ischemic

cardiomyopathy.

The Egyptian Heart Journal (2015) 67, 267–273

48-   Endothelial progenitor cells regenerate infracted myocardium with Neovascularization development

Journal of Advanced Research (2015) 6, 133–144

49- In-hospital subacute stent thrombosis with a huge thrombus Why? The patient, the lesion, or the stent?

Euro PCR Paris, 2015. (Oral presentation)

50- Clinical characteristics of hospitalized and ambulatory patients with heart failure- results from ESC heart failure long-term registry- Egyptian cohort

European Heart Failure, Seville, May 2015 (Poster)

51-   Demographic characteristics and in-hospital outcome of patients with pericardial diseases admitted to a tertiary care hospital

The European Society of Cardiology, London, 2015 (Poster )

52-   Open labeled non-Interventional study to assess efficacy & tolerability evaluation of Perindopril-amlodipine fixed-dose combination with or without the addition of diuretics for uncontrolled hypertensive patients in the clinical setting.

(oral presentation ) . ESH (European society of hypertension), Milano

, June 2015

53-   Statin treatment increases the circulating endothelial progenitor cells and improves endothelial function in patients with coronary artery diseases

The International Journal of Academic Research, Vol. 7. No. 3. Iss.2. May 2015

54-   Clinical characteristics and management of hospitalized and ambulatory patients with heart failure–results from ESC heart failure long-term registry–Egyptian cohort. ESC Heart Failure 2015; 2: 159– 167

55-   Circulating Endothelial Cells and Endothelial Function predict Major Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients with ST- Segment Elevation Myocardial Infarction

Journal of interventional cardiology, 2016 ;29: 89-98

56-   Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. The journal of international cardiology, 2016 ;203:909 -915

57- Eruptive Xanthoma: Combined Hyperlipidemia.

Medical & Clinical Reviews, 2016. Vol 2. No.4:31

58- Role of endothelial progenitor cells in management of myocardial infarction following total coronary occlusion in dogs.

Research Journal of Pharmaceutical, Biological, and Chemical Sciences 7(3), pp. 1225-1237 ,2016

59-      Utility of speckle tracking to predict the culprit vessel and recovery of left ventricular systolic function in patients with non-ST-elevation acute coronary

syndromes undergoing percutaneous coronary intervention.

European Heart Journal, 2016

60-   Preoperative Echocardiographic Assessment as a Predictor of Outcome after Liver Transplantation.

Transplant International, January 2017

61-2017 ESC/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

European Heart Journal, Volume 38, Issue 36, 21 September 2017,

Pages 2739–27 (Appendix)

62-  Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM). EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM

European Journal of Heart Failure (2017) 19, 1131–114

63-  New renal hemodynamic indices can predict worsening of renal function in acute decompensated heart failure

European Journal of Heart Failure, 2018 (abstract)

64-  Gender differences in Egyptian patients hospitalized with heart failure: insights from the European Society of Cardiology Heart Failure Long-Term Registry

ESC Heart Failure 2018; 5: 1159–1164

65 - Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: practical perspectives based on data from the

TREAT study

Clinical cardiology. 2018 ; 41(10):1322-1327

66-  Masked uncontrolled hypertension: Prevalence and predictors Egyptian Heart Journal 2018;70: 369–373

67-  Pattern of 24 hours ambulatory blood pressure readings in hypertensive patients with controlled office blood pressure measurements.

European Heart Journal, 2018

68-  Prognostic value of serum potassium levels among Egyptian patients hospitalized with acute heart failure: data from ESC Heart Failure registry

European Heart Failure, Athens, May 2019

69-  CardioEgypt 2019: Report from The Egyptian Society of Cardiology Annual Meeting in February 2019

European Heart Journal 2019; 40(20):1588-1589

70-  Contemporary Presentation and Management of Valvular Heart Disease The EURObservational Research Programme Valvular Heart Disease II Survey. Circulation. 2019; 140:1156–1169

71-  Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial

JAMACardiol.2019;4(3):273-2872-Once versus twice daily antihypertensive medications for the control of nocturnal blood pressure: a comparative study

Egyptian heart journal 2020; 72(9) : 1-7 . https://doi.org/10.1186/s43044-020-00045-5

73- Management of Coronary Disease in Patients with Advanced Kidney Disease.

ISCHEMIA-CKD

NEJM, March 30, 2020 (Supplementary Appendix).

74- Association of Sex with Severity of Coronary Artery Disease, Ischemia and Symptoms Burden in Patients with Moderate or Severe Ischemia

Secondary Analysis of the ISCHEMIA Randomized Clinical Trial JAMA Cardiology, March 30 , 2020

75- Rapid Guide to the Management of Cardiac Patients During the COVID- 19 Pandemic in Egypt. a position statement of the Egyptian Society of Cardiology

Egyptian heart journal 2020; 72(30) :1-9 . https://doi.org/10.1186/s43044-020-00061-5

76- Cardio Egypt 2020: Report from The Egyptian Society of Cardiology (EgSC) 47th. Annual Meeting in Cairo, Egypt 24-27 February 2020

European Heart Journal 2020; 41(20):1874-1875

77- European Society of Cardiology: Cardiovascular Disease Statistics 2019: ESC Atlas. European Heart Journal (2020) 41, 12-85

78- New renal hemodynamic indices can predict worsening of renal function in acute decompensated heart failure

ESC Heart Failure 2020 ;7(5) :2581-2588. DOI: 10.1002/ehf2.12835

79-   The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients. The Egyptian Heart Journal 2021; 73(20):1-11

80- Universal definition and classification of heart failure:

A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure 2021; 23: 352–380

81- Universal definition and classification of heart failure:

A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 2021: 27(4) :387-413

82-   Resilience with the crisis: cardiology department experience to cope with the coronavirus disease 2019 pandemic

Kasr Al Ainy Medical Journal 2020, 26:55–59

83-   The Diagnostic Value of the Relationship between Lipid Profile, the Different Grades of Coronary Calcification and Stenosis in Patients with Possible CAD. Annals of R.S.C.B., ISSN:1583-6258, Vol. 25, Issue 2, 2021, Pages. 3716 – 3736

84- Cardio Egypt 2021: one of the first physical meetings in the era of Covid-19. European Heart Journal (2021) 00, 1–doi:10.1093/eurheartj/ehab206

85- Patients profiling in Heart Failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 2021; 23(6): 872-881

86- Early results from an Egyptian transcatheter aortic valve registry (Egy- TVR). The Egyptian Heart Journal 2021; 73(67):1-8

87-2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 2021;42 (36): 3599 -

3726, https://doi.org/10.1093/eurheartj/ehab368

88-2021 ESC/EACTS Guidelines for the management of valvular heart disease.

European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 561–

632, https://doi.org/10.1093/eurheartj/ehab395

89-2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2021; 42(34): 3227-

3337 https://doi.org/10.1093/eurheartj/ehab484

90-2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal 2021;42: 3427-3520

91-  COVID-19 vaccination in patients with heart failure. A position paper of the Heart Failure Association of the European Society of Cardiology

European journal of heart failure 2021; 23: 1806–1818

92-  Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. ESC Heart Failure 2021;8: 4717–4736. DOI: 10.1002/ehf2.13643

93  - Contemporary Management of Severe Symptomatic Aortic Stenosis J Am Coll Cardiol 2021; 78:2131–2143

94  - Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction

ESC Heart Failure 2022 Apr;9(2):800-811

95- Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology

European Journal of heart failure 2022;24(2): 249-253.

https://doi.org/10.1002/ejhf.2430

96- European Society of Cardiology: Cardiovascular disease statistics 2021 European Heart Journal (2022) 43, 716–799 https://doi.org/10.1093/eurheartj/ehab892

97-   Cardiac remodeling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

European Journal of Heart Failure European Journal of Heart Failure (2022)24, 927–943

98-Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).

European Heart Journal (2022) 43, 2185–2195

99- Strategic Recommendations to Bridge the Gaps in Awareness, Diagnosis and Prevention of Heart Failure in the Middle East Region and Africa

Journal of the Saudi Heart Association 2022;34:53e65

100- Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry

European Journal of Heart Failure (2021)23, 2058–2069

101- Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey

European Heart Journal (2022) 00, 1–11 https://doi.org/10.1093/eurheartj/ehac209

102-   Cardiac remodeling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

European Journal of Heart Failure (2022)24,944-958 doi:10.1002/ejhf.2522

103-A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC-HFA EORP

Heart Failure Long-Term Registry

European Journal of Heart Failure (2022)24, 335–350 (appendix)

104-   Prevention of sudden death in heart failure with reduced ejection fraction: Do we still need ICD for primary prevention?

European Journal of Heart Failure (2022)24,1460–1466 https://doi.org/10.1002/ejhf.2594

105- Impact analysis of heart failure across European countries: an ESC-HFA position paper. ESC Heart Failure 2022; 9: 2767–2778. DOI: 10.1002/ehf2.14076

106-European Society of Cardiology: cardiovascular disease statistics 2021 European Heart Journal (2022) 43, 716–799

107-2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC- OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

European Heart Journal (2022) 43, 4229–4361 https://doi.org/10.1093/eurheartj/ehac244

108-2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)

European Heart Journal (2022) 00, 1–99 https://doi.org/10.1093/eurheartj/ehac270

109-2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden

cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC)

European Heart Journal (2022) 43, 3997–4126 https://doi.org/10.1093/eurheartj/ehac262

110-   2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS).

Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)

European Heart Journal (2022) 43, 3618–3731 https://doi.org/10.1093/eurheartj/ehac237

111- Congestion in Heart Failure: a circulating biomarker-based

Perspective. A review from the biomarkers working group of the Heart Failure Association, European Society of Cardiology

European Journal of Heart Failure (2022)24,1751–1766

112- European Society of Cardiology Quality Indicators for the Cardiovascular Preoperative Assessment and Management of patients considered for non-cardiac surgery. Developed in collaboration with the European Society of Anaesthesiology & Intensive Care

European Heart Journal - Quality of Care and Clinical Outcomes (2023) 9, 331–341

113- Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas

ESC Heart Failure 2022;9: 3713–3736. https://doi.org/10.1002/ehf2.14118

115-   Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications

American journal of preventive cardiology 13(2023)100456

116-  Detection and Diagnosis of Cardiac Amyloidosis in Egypt Cardiol Ther (2023) 12:197–213

117-   Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology

European Heart Journal - Quality of Care and Clinical Outcomes (2023) 0, 1–12

118-  Optimizing outcomes in heart failure: 2022 and beyond (Appendix A).

ESC Heart Failure April 2023 . https://doi.org/10.1002/ehf2.14363

119-  Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry

European Heart Journal 2020;41(39): 3787-3797

120-  Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. European Journal of Heart Failure (2021)23, 2058– 2069

121-  Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology

European Journal of Heart Failure 2023; 25: 776-791. doi:10.1002/ejhf.2874

122-   Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society

of Cardiology

European Journal of Heart Failure (2023); 25: 1025–1048 . doi:10.1002/ejhf.2918

123-  Management of HFpEF. Topic of the month, 6^th July ,2023 ESC website

124-   Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC European Journal of Heart Failure 2023;25(7): 1115-1131 .doi:10.1002/ejhf.2888

125-   Regional expert opinion: Heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey

ESC Heart Failure 2023;10: 2773–2787

126-   Current status of outpatient heart failure management in Egypt and recommendations for the future

ESC Heart Failure2023;10: 2788–2796

127-   Thrombo-embolic events in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. European Journal of Heart Failure April 2023 .

https://doi.org/10.1002/ejhf.2871

128-   Clinical Features, Socioeconomic Status, Management, and Outcomes of Acute Heart Failure: PEACE MENA Registry Phase I Results.

Current Vascular Pharmacology , May 2023

129-   2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes . European Heart Journal (2023) ; 44 (39) : 4043- 4140 https://doi.org/10.1093/eurheartj/ehad192

130-   2023 ESC Guidelines for the management of endocarditis European Heart Journal (2023) ;44 (39):3948- 4042 https://doi.org/10.1093/eurheartj/ehad193

131-2023 ESC Guidelines for the management of cardiomyopathies European Heart Journal (2023) ;44 (37): 3503- 3626 https://doi.org/10.1093/eurheartj/ehad194

132-   2023 ESC Guidelines for the management of acute coronary syndromes European Heart Journal (2023) ;44: 3720 -3826 https://doi.org/10.1093/eurheartj/ehad191

133-   State-of-the-art document on optimal contemporary management of

Cardiomyopathies. European Journal of Heart Failure (2023); 25 :1899-1922 doi:10.1002/ejhf.2979

134-  Incidence, risk assessment and prevention of sudden cardiac death in Cardiomyopathies. European Journal of Heart Failure (2023) ;25:2144-2163 doi:10.1002/ejhf.3076

135-  Baseline predictors of final infarct size in patients with ST elevation myocardial infarction undergoing primary PCI.

European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.210, https://doi.org/10.1093/eurheartj/ehad655.210

136-  Rationale and design of the ESC Heart Failure III Registry – Implementation and Discovery. European Journal of Heart Failure (2023) doi:10.1002/ejhf.3087

137-  Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart

Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

European Journal of Heart Failure (2024). doi:10.1002/ejhf.3106

138-   Clinical features, socioeconomic status, management, short and long-term outcomes of patients with acute myocardial infarction: Phase I results of PEACE MENA registry

PLoS ONE 2024, 19(1 January), e0296056

139-   Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: A systematic review and meta-analysis

Diabetes and Metabolic Syndrome: Clinical Research and Reviewsd., 2024, 18(1), 102938

140-   Expert Recommendations to Bridge Gaps in Heart Failure Patient Support in the Middle East and Africa Region

Anatolian Journal of Cardiology, 2024, 28(1), pp. 2–22

141-  Assessing and improving radiation safety in cardiac catheterization: a study from Cairo University Hospital 2024; 76 (17):

142-   How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC

European Journal of Heart Failure (2024) doi:10.1002/ejhf.3295

143-   Differences in presentation, diagnosis and management of heart failure in women.A scientific statement of the Heart Failure Association of the ESC

European Journal of Heart Failure (2024) 26, 1669–1686

144-   Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure (2024) doi:10.1002/ejhf.3323

145-   Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

Circulation: Cardiovascular Intervention2024; 17(6):457-473

146-  Case Report: concurrent myocardial and cerebral infarction due to aortic thrombus European Heart Journal - Case Reports (2023) 7, 1–5

147-  Baseline characteristics and outcomes of rheumatic mitral valve disease: the EURObservational Research Programme Valvular Heart Disease II Survey European Heart Journal , 2025

Research Projects :

-   A multicenter Randomized comparative study for assessing the efficacy and safety

of Amlodipine versus Isosorbide 5–mononitrate in the treatment of symptomatic myocardial ischemia ,1997 .( Multicenter

International Study, Pfizer )

-   Study Coordinator of the SAGE study (Study Assessing Goals in the Elderly): Multicenter International Study,2001 (supervised by Pfizer).

-   Member of EHS working group and advisory board on cardiovascular prevention guidelines in Egypt (Delta –C project), 2005.

-Principal investigator in Euro heart failure registry study, The European society of cardiology, 2011 ( Kasr Al Aini, Cairo University site )

-Principal investigator in EURObservational Research Programme – Peripartum Cardiomyopathy (PPCM) : Long-Term Registry on patients with peripartum cardiomyopathy, The European society of cardiology, June , 2012.

-Principal investigator in a multicenter international study: EXAMINE

“A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with

an Alogliptin, in Addition to Standard of Care, in Subjects with Type 2 Diabetes and Acute Coronary Syndrome” .,2011

-   Co-investigator in European study: Exercise training in heart failure pitfalls ExTraHF survey. Euro HF meeting, Athens, 2014

-    Region׳s Committee member of the thrombosis management in practice (TMIP program) (workshop at London, 26-27 November, 2014 )

-         Steering committee member of the CONTROL trial

Open labeled non-Interventional study to assess efficacy & tolerability evaluation of Perindopril-amlodipine fixed-dose combination with or without the addition of diuretics for uncontrolled hypertensive patients in the clinical setting. November 2014

(presented at the European society of hypertension, Rome, 2015)

-         Principal investigator of the project of Cairo University observational study of cardiac amyloidosis in patients with left ventricular hypertrophy (2022-2025)

-         Principal investigator in the multicenter international world heart failure registry (REPORT –HF ,2014-2018) .( Kasr Al Aini,Cairo University site )

-         Principal investigator in a multicenter international study : ISCHEMIA International Study of Comparative Health Effectiveness with Medical and Invasive Approaches ( Kasr Al Aini , Cairo University site )

-         National coordinator for the European Valvular Heart Disease (VHD II) Survey/Registry ,2016

-         National coordinator for the European Heart Failure Registry ,2019

-         Principal Investigator in the PEACE MENA Registry ,2019

Chairman of scientific meetings:

-         Stem cell day, faculty of medicine, Cairo University, December, 2014

-         The annual heart failure meeting, the Egyptian society of cardiology, October, 2015

-         The annual heart failure meeting, the Egyptian society of cardiology, October 2017

-         The annual heart failure meeting, the Egyptian society of cardiology, October, 2018

-         The annual heart failure meeting, the Egyptian society of cardiology, October,

2019